{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:12:16Z","timestamp":1783901536119,"version":"3.55.0"},"reference-count":17,"publisher":"Walter de Gruyter GmbH","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Drug-induced immune hemolytic anemia (DIIHA) represents a rare but dangerous medical condition that more often affects children who are administered cephalosporins. A 10-year-old girl developed severe hemolysis after administration of cefuroxime and ceftriaxone for treating an infection linked to parotid lymphangioma. The patient had previously tolerated ceftriaxone and clindamycin but developed dizziness, pallor, and tachycardia, and her hemoglobin (Hb) levels decreased from 12.9 to 2.6 g\/dL during her fourth day of treatment, which led to hypovolemic shock and transient renal dysfunction. Our objective is to establish cefuroxime and ceftriaxone as the responsible drugs for DIIHA through immunohematologic testing. The laboratory tests included the direct antiglobulin test (DAT) and the indirect antiglobulin test (IAT) along with drug-dependent antibody testing using the patient\u2019s serum (1) to react against group O red blood cells (RBCs) treated with cefuroxime and (2) to react separately against group O RBCs not treated with, but in the presence of, ceftriaxone, with and without complement, at both room temperature and by the IAT. The DAT showed positivity for IgG and C3d. The patient\u2019s serum reacted with cefuroxime-treated RBCs by the IAT and reacted with untreated RBCs when ceftriaxone and complement were present. The laboratory results showed that drug-dependent antibodies were present to target RBCs. The patient\u2019s condition improved rapidly after stopping cephalosporins and starting ciprofloxacin\/levofloxacin and clindamycin, which resulted in an Hb increase to 9.1 g\/dL within 48 hours and the absence of hemoglobinuria. This case shows why health care professionals must identify DIIHA early through diagnostic testing even when patients have shown previous tolerance to antibiotics. This case report also shows that both cefuroxime and ceftriaxone were the drugs responsible for the DIIHA.<\/jats:p>","DOI":"10.2478\/immunohematology-2025-016","type":"journal-article","created":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T13:26:50Z","timestamp":1767965210000},"page":"111-116","source":"Crossref","is-referenced-by-count":1,"title":["Cephalosporin-induced hemolytic anemia: a case study"],"prefix":"10.2478","volume":"41","author":[{"given":"Gra\u00e7a","family":"Almeida","sequence":"first","affiliation":[{"name":"Reference Laboratory of Immunohematology, Portuguese Institute of Blood and Transplantation, IPST, IP , Lisbon , Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Costa","sequence":"additional","affiliation":[{"name":"Immunohemotherapy and Transfusional Medicine\u2013Hemovida, Hospital Beatriz \u00c2ngelo , Lisbon , Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eug\u00e9nia","family":"Vasconcelos","sequence":"additional","affiliation":[{"name":"Immunohemotherapy and Transfusional Medicine, IPST, IP , Lisbon , Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2025,12,31]]},"reference":[{"key":"2026071214322045697_j_immunohematology-2025-016_ref_001","unstructured":"Cohn CS, Delaney M, Johnson ST, et al., Eds. Technical manual. 21st ed. Bethesda, MD: AABB, 2023."},{"key":"2026071214322045697_j_immunohematology-2025-016_ref_002","doi-asserted-by":"crossref","unstructured":"Garratty G. Drug-induced immune hemoly tic anemia. Hematology Am Soc Hematol Educ Program 2009:73\u20139.","DOI":"10.1182\/asheducation-2009.1.73"},{"key":"2026071214322045697_j_immunohematology-2025-016_ref_003","doi-asserted-by":"crossref","unstructured":"Kumar S, Bansal R, Bansal P, Dhamija RK. Ceftriaxone-induced hemolytic anemia: a rare case report. Perm J 2020;24:19.088.","DOI":"10.7812\/TPP\/19.088"},{"key":"2026071214322045697_j_immunohematology-2025-016_ref_004","doi-asserted-by":"crossref","unstructured":"Vehapoglu A, G\u00f6knar N, Tuna R, Cakir FB. Ceftriaxone-induced hemolytic anemia in a child successfully managed with intravenous immunoglobulin. Turk J Pediatr 2016; 58:216\u20136. doi: 10.24953\/turkjped.2016.02.016.","DOI":"10.24953\/turkjped.2016.02.016"},{"key":"2026071214322045697_j_immunohematology-2025-016_ref_005","doi-asserted-by":"crossref","unstructured":"Johnson ST, Fueger JT, Gottschall JL. One center\u2019s experience: the serology and drugs associated with drug-induced immune hemolytic anemia: a new paradigm. Transfusion 2007;47:697\u2013702. doi: 10.1111\/j.1537-2995.2007.01173.x.","DOI":"10.1111\/j.1537-2995.2007.01173.x"},{"key":"2026071214322045697_j_immunohematology-2025-016_ref_006","doi-asserted-by":"crossref","unstructured":"Mayer B, Bartolm\u00e4s T, Y\u00fcrek S, Salama A. Variability of findings in drug-induced immune hemoly tic anemia: experience over 20 years in a single center. Transfus Med Hemother 2015;42:333\u20139. doi: 10.1159\/000440673.","DOI":"10.1159\/000440673"},{"key":"2026071214322045697_j_immunohematology-2025-016_ref_007","doi-asserted-by":"crossref","unstructured":"Arndt PA, Leger RM, Garratty G. Serology of antibodies to second- and third-generation cephalosporins associated with immune hemolytic anemia and\/or positive direct antiglobulin tests. Transfusion 1999;39:1239\u201346. doi: 10.1046\/j.1537-2995.1999.39111239.x.","DOI":"10.1046\/j.1537-2995.1999.39111239.x"},{"key":"2026071214322045697_j_immunohematology-2025-016_ref_008","doi-asserted-by":"crossref","unstructured":"Leicht HB, Weinig E, Mayer B, Viebahn J, Geier A, Rau M. Ceftriaxone-induced hemoly tic anemia with severe renal failure: a case report and review of literature. BMC Pharmacol Toxicol 2018;19. doi: 10.1186\/s40360-018-0257-7.","DOI":"10.1186\/s40360-018-0257-7"},{"key":"2026071214322045697_j_immunohematology-2025-016_ref_009","doi-asserted-by":"crossref","unstructured":"Petz LD, Garratty G. Immune hemolytic anemia. 2nd ed. Philadelphia, PA: Churchill Livingstone, 2005.","DOI":"10.1016\/B978-0-443-08559-8.50012-1"},{"key":"2026071214322045697_j_immunohematology-2025-016_ref_010","doi-asserted-by":"crossref","unstructured":"Branch DR. Drug-induced immune hemolytic anemias. ISBT Sci Ser 2019;14:49\u201352.","DOI":"10.1111\/voxs.12469"},{"key":"2026071214322045697_j_immunohematology-2025-016_ref_011","doi-asserted-by":"crossref","unstructured":"Bougie DW, Wilker PR, Aster RH. Patients with quinine- induced immune thrombocy topenia have both \u201cdrug-dependent\u201d and \u201cdrug-specific\u201d antibodies. Blood 2006;108: 922\u20137.","DOI":"10.1182\/blood-2006-01-009803"},{"key":"2026071214322045697_j_immunohematology-2025-016_ref_012","doi-asserted-by":"crossref","unstructured":"Zhu J, Zhu J, Bougie DW, Aster RH, Springer TA. Structural basis for quinine-dependent antibody binding to platelet integrin \u03b1IIb\u03b23. Blood 2015;126:2138\u201345.","DOI":"10.1182\/blood-2015-04-639351"},{"key":"2026071214322045697_j_immunohematology-2025-016_ref_013","doi-asserted-by":"crossref","unstructured":"Malloy CA, Kiss JE, Challapalli M. Cefuroxime-induced immune hemolysis. J Pediatr 2003;143:130\u20132.","DOI":"10.1016\/S0022-3476(03)00210-5"},{"key":"#cr-split#-2026071214322045697_j_immunohematology-2025-016_ref_014.1","doi-asserted-by":"crossref","unstructured":"Barton LL. Cefuroxime-induced immune hemolysis. J Pediatr 2004;144:690","DOI":"10.1016\/j.jpeds.2004.01.038"},{"key":"#cr-split#-2026071214322045697_j_immunohematology-2025-016_ref_014.2","doi-asserted-by":"crossref","unstructured":"author reply: 690. doi: 10.1016\/j.jpeds. 2004.01.038.","DOI":"10.1088\/1126-6708\/2004\/01\/038"},{"key":"2026071214322045697_j_immunohematology-2025-016_ref_015","doi-asserted-by":"crossref","unstructured":"Arndt PA, Garratty G. Cross-reactivity of cefotetan and ceftriaxone antibodies, associated with hemolytic anemia, with other cephalosporins and penicillin. Am J Clin Pathol 2002;118:256\u201362. doi: 10.1309\/jfje-vukn-221t-g6ev.","DOI":"10.1309\/JFJE-VUKN-221T-G6EV"},{"key":"2026071214322045697_j_immunohematology-2025-016_ref_016","doi-asserted-by":"crossref","unstructured":"Sharma A, Chamberlain S, Mannuru D, Matta A. A n uncommon incidence of drug-induced immune hemolytic anemia secondary to ceftriaxone. Cureus 2021. doi: 10.7759\/ cureus.20682.","DOI":"10.7759\/cureus.20682"}],"container-title":["Immunohematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/reference-global.com\/pdf\/10.2478\/immunohematology-2025-016","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:01:40Z","timestamp":1783900900000},"score":1,"resource":{"primary":{"URL":"https:\/\/reference-global.com\/article\/10.2478\/immunohematology-2025-016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,1]]},"references-count":17,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,12,31]]},"published-print":{"date-parts":[[2025,12,1]]}},"alternative-id":["10.2478\/immunohematology-2025-016"],"URL":"https:\/\/doi.org\/10.2478\/immunohematology-2025-016","relation":{},"ISSN":["1930-3955"],"issn-type":[{"value":"1930-3955","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,1]]}}}